Company news

Neuren Pharmaceuticals Limited news in 2021

Neuren Pharmaceuticals Limited's news releases, calls and decks from 2021, newest first.

View company

Positive topline results from Phase 3 trial in Rett syndrome

December 6, 2021

Neuren presenting at Bell Potter Healthcare Conference

November 9, 2021

Q3 2021 quarterly activity and cash flow report

October 27, 2021

Neuren receives feedback on IND for Phelan-McDermid syndrome

October 21, 2021

US patent to 2034 granted for Neurens NNZ-2591 in autism

October 10, 2021

$3.3 million raised from oversubscribed SPP

October 5, 2021

Feedback on Angelman IND and submission of Pitt Hopkins IND

October 1, 2021

IND application submitted for NNZ-2591 in Phelan-McDermid

September 20, 2021

Share Purchase Plan Offer Booklet

September 16, 2021

New patent issued to 2032 for Neurens trofinetide in Brazil

September 16, 2021

Investor Presentation, 13 September 2021

September 12, 2021

Proposed issue of securities - NEU

September 12, 2021

Placement to accelerate NNZ-2591 across 4 indications

September 12, 2021

FDA grants Orphan Drug designation for Prader-Willi syndrome

September 3, 2021

Angelman IND and Ethics applications submitted for NNZ-2591

August 31, 2021

R&D Tax Incentive Advance Overseas Finding Approval

August 30, 2021

Phase 3 enrolment successfully completed, results in Q4 2021

August 4, 2021

Q2 2021 quarterly activity and cash flow report

July 30, 2021

Positive FDA meetings enable INDs for three Phase 2 trials

May 31, 2021

New patent issued to 2032 for Neurens trofinetide in Canada

April 28, 2021

Quarterly report and cash flow statement for Q1 2021

April 22, 2021

S&P DJI Announces March 2021 Quarterly Rebalance

March 12, 2021

Neuren successfully completes manufacturing for Phase 2

March 9, 2021

Neuren approaching transforming milestones in 2021

February 23, 2021

Preliminary Final Report and 2020 full year accounts

February 23, 2021

Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline

February 15, 2021

Successful Phase 1 trial for Neurens NNZ-2591

February 14, 2021

Quarterly report and cash flow statement for Q4 2020

January 28, 2021

European Commission grants 3 NNZ-2591 Orphan designations

January 10, 2021

Decks in 2021